Objective:To investigate the clinical application effect of ciprofol combined with low-dose esketamine in painless gastrointestinal endoscopy.Methods:A retrospective analysis was conducted on the clinical data of 160 ...Objective:To investigate the clinical application effect of ciprofol combined with low-dose esketamine in painless gastrointestinal endoscopy.Methods:A retrospective analysis was conducted on the clinical data of 160 patients who underwent painless gastrointestinal endoscopy at the Digestive Endoscopy Center of Chengdu Integrated Traditional Chinese and Western Medicine Hospital from June 2023 to June 2024.The patients were divided into a control group(ciprofol+sufentanil,n=80)and a study group(ciprofol+esketamine,n=80)based on the anesthesia protocol they received.Hemodynamic indicators[mean arterial pressure(MAP),heart rate(HR),and blood oxygen saturation(SpO2)],anesthesia-related indicators,sedation effectiveness,and the incidence of adverse events were observed and compared between the two groups at different time points during the examination.Results:The fluctuations in HR and MAP at three time points(after induction,during endoscope insertion,and during the examination)were significantly smaller in the study group than in the control group(all P<0.05),indicating more stable hemodynamics.The total amount of sedative drugs used,the number of additional sedative doses administered,and the time spent in the post-anesthesia care unit were significantly lower in the study group than in the control group(all P<0.05).There was no significant difference in the success rate of sedation between the two groups(98.75%vs.96.25%,P>0.05).The incidence of adverse events was lower in the study group than in the control group(3.75%vs.13.75%,P<0.05).Conclusion:The use of low-dose esketamine as an adjuvant analgesic drug based on ciprofol sedation can effectively maintain hemodynamic stability,reduce the amount of sedative drugs used,facilitate rapid recovery of patients,and lower the risk of adverse events.展开更多
BACKGROUND Ciprofol is a novel agent for intravenous general anesthesia.In February 2022,it was approved by the National Medical Products Administration for general anesthesia induction and maintenance.It has the adva...BACKGROUND Ciprofol is a novel agent for intravenous general anesthesia.In February 2022,it was approved by the National Medical Products Administration for general anesthesia induction and maintenance.It has the advantages of fast onset,fast elimination,stable circulation,and few adverse reactions.However,the efficacy and safety of ciprofol in cardiac surgery with cardiopulmonary bypass have not been reported.Here we describe a case where ciprofol was successfully used for anesthesia in cardiac surgery with cardiopulmonary bypass.CASE SUMMARY A 72-year-old man(height 176 cm;weight 70 kg)was diagnosed with coronary atherosclerotic cardiomyopathy requiring coronary artery bypass grafting and left ventricular aneurysmectomy.Ciprofol was administered for induction(0.4 mg/kg)and maintenance(0.6-1.0 mg/kg/h)of general anesthesia.During the entire operation,the bispectral index,hemodynamics,and blood oxygen saturation were maintained at normal levels.The patient recovered well after surgery,with no serious adverse events related to ciprofol.CONCLUSION Ciprofol is safe and effective for anesthesia in cardiac surgery with cardiopulmonary bypass.展开更多
Background and Objectives: Propofol is a commonly used intravenous anesthetic for painless artificial abortion, but the injection pain and related adverse reactions such as those related to respiration and circulation...Background and Objectives: Propofol is a commonly used intravenous anesthetic for painless artificial abortion, but the injection pain and related adverse reactions such as those related to respiration and circulation it induces have also been criticized. We aimed to conduct a comparative study on the efficacy, safety and comfort of ciprofol and propofol applied in painless artificial abortion. Materials and Methods: A total of 140 early pregnant patients undergoing painless induced abortion were selected and randomly divided into the ciprofol combined with fentanyl group (Group C) and the propofol combined with fentanyl group (Group P), with 70 cases in each group. The anesthetic effect, depth of anesthesia sedation (NI), onset time, recovery time, recovery time of orientation, retention time in the anesthesia recovery room and total amount of intravenous anesthetic drug were recorded in both groups. The respiratory rate (RR), oxygen saturation (SpO2), mean arterial pressure (MAP), and heart rate (HR) at different time points were recorded. The occurrence of perioperative adverse events, injection pain, postoperative nausea and vomiting, and dizziness were compared. The pain score at 30 minutes after operation and the satisfaction of patients and surgeons with anesthesia were evaluated. Results: The success rate of anesthesia in both groups was 100%. There were no statistically significant differences in the NI value at each time point, intraoperative body movement, recovery time, recovery time of orientation, retention time in the anesthesia recovery room, and total dosage of sedative drugs (ml) between the two groups;the onset time in Group C was longer than that in Group P, with a statistically significant difference (P Conclusion: The efficacy of ciprofol in painless induced abortion is equivalent to that of propofol, and the incidence of adverse reactions is lower than that of propofol, with higher safety and comfort.展开更多
Ciprofol,as a new type of short-acting intravenous anesthetic drug,belongs to the category of gamma-aminobutyric acid(GABA)receptor agonists.Its unique chemical structure,through the introduction of the cyclopropyl gr...Ciprofol,as a new type of short-acting intravenous anesthetic drug,belongs to the category of gamma-aminobutyric acid(GABA)receptor agonists.Its unique chemical structure,through the introduction of the cyclopropyl group in the isopropyl side chain of propofol,constructs a new type of chiral molecule,which significantly enhances the spatial effect,and improves the affinity for GABA receptors.Its pharmacological properties are characterized by high potency,rapid onset of action,rapid recovery,low accumulation,and minimal adverse reactions.Therefore,it has a wide range of applications in various endoscopic diagnostic and therapeutic operations,ICU sedation,and general anesthesia.In this paper,the related knowledge of ciprofol and the development of clinical application research are comprehensively sorted out and synthesized,to provide a solid theoretical basis for the rational application of ciprofol in clinical practice.At the same time,the future research direction of ciprofol will also be prospected to provide valuable references for research in related fields.展开更多
目的系统评价环泊酚用于全身麻醉/深度镇静的效果与安全性。方法通过计算机系统,全面检索万方数据知识服务平台、维普网、中国知网、中国生物医学文献数据库、PubMed、Cochrane、Embase、Web of Science等数据库,检索时间从建库至2024年...目的系统评价环泊酚用于全身麻醉/深度镇静的效果与安全性。方法通过计算机系统,全面检索万方数据知识服务平台、维普网、中国知网、中国生物医学文献数据库、PubMed、Cochrane、Embase、Web of Science等数据库,检索时间从建库至2024年1月。严格筛选以环泊酚为干预组、丙泊酚为对照组用于全身麻醉/深度镇静的随机对照试验文献。根据明确的纳入标准、排除标准及文献质量评价,对筛选出的文献进行细致分析。采用Revman 5.4软件进行综合的Meta分析。结果共纳入文献31篇,涉及患者4580例。Meta分析结果显示,干预组与对照组麻醉诱导成功时间比较差异无统计学意义[MD=2.62,95%CI(-4.35,9.60),P=0.46],干预组麻醉苏醒时间较对照组长[MD=0.44,95%CI(0.08,0.81),P=0.02];干预组患者及麻醉科医师满意度评分较对照组高[MD=1.10,95%CI(0.15,2.05),P=0.02;MD=0.78,95%CI(0.13,1.43),P=0.02],干预组与对照组内镜医师满意度比较差异无统计学意义[MD=0.40,95%CI(-0.28,1.07),P=0.25];干预组麻醉诱导前后血氧饱和度、平均动脉压差值较对照组小[MD=0.75,95%CI(0.03,1.47),P=0.04;MD=3.90,95%CI(2.33,5.47),P<0.00001],干预组与对照组麻醉诱导前后脑电双频指数与心率差值比较差异无统计学意义(P>0.05);干预组不良反应总发生率及低血压、注射痛、低氧血症发生率较对照组低[OR=0.37,95%CI(0.22,0.64),P=0.0003;OR=0.54,95%CI(0.41,0.71),P<0.0001;OR=0.07,95%CI(0.04,0.11),P<0.00001;OR=0.48,95%CI(0.36,0.65),P<0.00001],干预组与对照组心动过缓、高血压、恶心呕吐发生率比较差异无统计学意义(P>0.05)。结论全身麻醉/深度镇静中环泊酚的麻醉效果与丙泊酚相当,且安全性优于丙泊酚。展开更多
Background:Ciprofol(HSK3486;Haisco Pharmaceutical Group Co.,Ltd.,Chengdu,China),developed as a novel 2,6-disubstituted phenol derivative showed similar tolerability and efficacy characteristics as propofol when applic...Background:Ciprofol(HSK3486;Haisco Pharmaceutical Group Co.,Ltd.,Chengdu,China),developed as a novel 2,6-disubstituted phenol derivative showed similar tolerability and efficacy characteristics as propofol when applicated as continuous intravenous infusion for 12 h maintenance sedation in a previous phase 1 trial.The phase 2 trial was designed to investigate the safety,efficacy,and pharmacokinetic characteristics of ciprofol for sedation of patients undergoing mechanical ventilation.Methods:In this multicenter,open label,randomized,propofol positive-controlled,phase 2 trial,39 Chinese intensive care unit patients receiving mechanical ventilation were enrolled and randomly assigned to a ciprofol or propofol group in a 2:1 ratio.The ciprofol infusion was started with a loading infusion of 0.1-0.2 mg/kg for 0.5-5.0 min,followed by an initial maintenance infusion rate of 0.30 mg·kg^(-1)·h^(-1),which could be adjusted to an infusion rate of 0.06 to 0.80 mg·kg^(-1)·h^(-1),whereas for propofol the loading infusion dose was 0.5-1.0 mg/kg for 0.5-5.0 min,followed by an initial maintenance infusion rate of 1.50 mg·kg^(-1)·h^(-1),which could be adjusted to 0.30-4.00 mg·kg^(-1)·h^(-1)to achieve-2 to+1 Richmond Agitation-Sedation Scale sedation within 6-24 h of drug administration.Results:Of the 39 enrolled patients,36 completed the trial.The median(min,max)of the average time to sedation compliance values for ciprofol and propofol were 60.0(52.6,60.0)min and 60.0(55.2,60.0)min,with median difference of 0.00(95%confidence interval:0.00,0.00).In total,29(74.4%)patients comprising 18(69.2%)in the ciprofol and 11(84.6%)in the propofol group experienced 86 treatment emergent adverse events(TEAEs),the majority being of severity grade 1 or 2.Drug-and sedation-related TEAEs were hypotension(7.7%vs.23.1%,P=0.310)and sinus bradycardia(3.8%vs.7.7%,P=1.000)in the ciprofol and propofol groups,respectively.The plasma concentration-time curves for ciprofol and propofol were similar.Conclusions:ciprofol is comparable to propofol with good tolerance and efficacy for sedation of Chinese intensive care unit patients undergoing mechanical ventilation in the present study setting.Trial registration:ClinicalTrials.gov,NCT04147416.展开更多
基金China Red Cross Foundation Medical Empowerment Special Fund-“Medical Empowerment and Talent Cultivation Program”Clinical Research ProjectProject Title:A Clinical Study on the Use of Esketamine at Different Dosages Combined with Propofol for Painless Gastroscopy(Project No.:GCP-2022-022)。
文摘Objective:To investigate the clinical application effect of ciprofol combined with low-dose esketamine in painless gastrointestinal endoscopy.Methods:A retrospective analysis was conducted on the clinical data of 160 patients who underwent painless gastrointestinal endoscopy at the Digestive Endoscopy Center of Chengdu Integrated Traditional Chinese and Western Medicine Hospital from June 2023 to June 2024.The patients were divided into a control group(ciprofol+sufentanil,n=80)and a study group(ciprofol+esketamine,n=80)based on the anesthesia protocol they received.Hemodynamic indicators[mean arterial pressure(MAP),heart rate(HR),and blood oxygen saturation(SpO2)],anesthesia-related indicators,sedation effectiveness,and the incidence of adverse events were observed and compared between the two groups at different time points during the examination.Results:The fluctuations in HR and MAP at three time points(after induction,during endoscope insertion,and during the examination)were significantly smaller in the study group than in the control group(all P<0.05),indicating more stable hemodynamics.The total amount of sedative drugs used,the number of additional sedative doses administered,and the time spent in the post-anesthesia care unit were significantly lower in the study group than in the control group(all P<0.05).There was no significant difference in the success rate of sedation between the two groups(98.75%vs.96.25%,P>0.05).The incidence of adverse events was lower in the study group than in the control group(3.75%vs.13.75%,P<0.05).Conclusion:The use of low-dose esketamine as an adjuvant analgesic drug based on ciprofol sedation can effectively maintain hemodynamic stability,reduce the amount of sedative drugs used,facilitate rapid recovery of patients,and lower the risk of adverse events.
文摘BACKGROUND Ciprofol is a novel agent for intravenous general anesthesia.In February 2022,it was approved by the National Medical Products Administration for general anesthesia induction and maintenance.It has the advantages of fast onset,fast elimination,stable circulation,and few adverse reactions.However,the efficacy and safety of ciprofol in cardiac surgery with cardiopulmonary bypass have not been reported.Here we describe a case where ciprofol was successfully used for anesthesia in cardiac surgery with cardiopulmonary bypass.CASE SUMMARY A 72-year-old man(height 176 cm;weight 70 kg)was diagnosed with coronary atherosclerotic cardiomyopathy requiring coronary artery bypass grafting and left ventricular aneurysmectomy.Ciprofol was administered for induction(0.4 mg/kg)and maintenance(0.6-1.0 mg/kg/h)of general anesthesia.During the entire operation,the bispectral index,hemodynamics,and blood oxygen saturation were maintained at normal levels.The patient recovered well after surgery,with no serious adverse events related to ciprofol.CONCLUSION Ciprofol is safe and effective for anesthesia in cardiac surgery with cardiopulmonary bypass.
文摘Background and Objectives: Propofol is a commonly used intravenous anesthetic for painless artificial abortion, but the injection pain and related adverse reactions such as those related to respiration and circulation it induces have also been criticized. We aimed to conduct a comparative study on the efficacy, safety and comfort of ciprofol and propofol applied in painless artificial abortion. Materials and Methods: A total of 140 early pregnant patients undergoing painless induced abortion were selected and randomly divided into the ciprofol combined with fentanyl group (Group C) and the propofol combined with fentanyl group (Group P), with 70 cases in each group. The anesthetic effect, depth of anesthesia sedation (NI), onset time, recovery time, recovery time of orientation, retention time in the anesthesia recovery room and total amount of intravenous anesthetic drug were recorded in both groups. The respiratory rate (RR), oxygen saturation (SpO2), mean arterial pressure (MAP), and heart rate (HR) at different time points were recorded. The occurrence of perioperative adverse events, injection pain, postoperative nausea and vomiting, and dizziness were compared. The pain score at 30 minutes after operation and the satisfaction of patients and surgeons with anesthesia were evaluated. Results: The success rate of anesthesia in both groups was 100%. There were no statistically significant differences in the NI value at each time point, intraoperative body movement, recovery time, recovery time of orientation, retention time in the anesthesia recovery room, and total dosage of sedative drugs (ml) between the two groups;the onset time in Group C was longer than that in Group P, with a statistically significant difference (P Conclusion: The efficacy of ciprofol in painless induced abortion is equivalent to that of propofol, and the incidence of adverse reactions is lower than that of propofol, with higher safety and comfort.
文摘Ciprofol,as a new type of short-acting intravenous anesthetic drug,belongs to the category of gamma-aminobutyric acid(GABA)receptor agonists.Its unique chemical structure,through the introduction of the cyclopropyl group in the isopropyl side chain of propofol,constructs a new type of chiral molecule,which significantly enhances the spatial effect,and improves the affinity for GABA receptors.Its pharmacological properties are characterized by high potency,rapid onset of action,rapid recovery,low accumulation,and minimal adverse reactions.Therefore,it has a wide range of applications in various endoscopic diagnostic and therapeutic operations,ICU sedation,and general anesthesia.In this paper,the related knowledge of ciprofol and the development of clinical application research are comprehensively sorted out and synthesized,to provide a solid theoretical basis for the rational application of ciprofol in clinical practice.At the same time,the future research direction of ciprofol will also be prospected to provide valuable references for research in related fields.
文摘目的系统评价环泊酚用于全身麻醉/深度镇静的效果与安全性。方法通过计算机系统,全面检索万方数据知识服务平台、维普网、中国知网、中国生物医学文献数据库、PubMed、Cochrane、Embase、Web of Science等数据库,检索时间从建库至2024年1月。严格筛选以环泊酚为干预组、丙泊酚为对照组用于全身麻醉/深度镇静的随机对照试验文献。根据明确的纳入标准、排除标准及文献质量评价,对筛选出的文献进行细致分析。采用Revman 5.4软件进行综合的Meta分析。结果共纳入文献31篇,涉及患者4580例。Meta分析结果显示,干预组与对照组麻醉诱导成功时间比较差异无统计学意义[MD=2.62,95%CI(-4.35,9.60),P=0.46],干预组麻醉苏醒时间较对照组长[MD=0.44,95%CI(0.08,0.81),P=0.02];干预组患者及麻醉科医师满意度评分较对照组高[MD=1.10,95%CI(0.15,2.05),P=0.02;MD=0.78,95%CI(0.13,1.43),P=0.02],干预组与对照组内镜医师满意度比较差异无统计学意义[MD=0.40,95%CI(-0.28,1.07),P=0.25];干预组麻醉诱导前后血氧饱和度、平均动脉压差值较对照组小[MD=0.75,95%CI(0.03,1.47),P=0.04;MD=3.90,95%CI(2.33,5.47),P<0.00001],干预组与对照组麻醉诱导前后脑电双频指数与心率差值比较差异无统计学意义(P>0.05);干预组不良反应总发生率及低血压、注射痛、低氧血症发生率较对照组低[OR=0.37,95%CI(0.22,0.64),P=0.0003;OR=0.54,95%CI(0.41,0.71),P<0.0001;OR=0.07,95%CI(0.04,0.11),P<0.00001;OR=0.48,95%CI(0.36,0.65),P<0.00001],干预组与对照组心动过缓、高血压、恶心呕吐发生率比较差异无统计学意义(P>0.05)。结论全身麻醉/深度镇静中环泊酚的麻醉效果与丙泊酚相当,且安全性优于丙泊酚。
文摘Background:Ciprofol(HSK3486;Haisco Pharmaceutical Group Co.,Ltd.,Chengdu,China),developed as a novel 2,6-disubstituted phenol derivative showed similar tolerability and efficacy characteristics as propofol when applicated as continuous intravenous infusion for 12 h maintenance sedation in a previous phase 1 trial.The phase 2 trial was designed to investigate the safety,efficacy,and pharmacokinetic characteristics of ciprofol for sedation of patients undergoing mechanical ventilation.Methods:In this multicenter,open label,randomized,propofol positive-controlled,phase 2 trial,39 Chinese intensive care unit patients receiving mechanical ventilation were enrolled and randomly assigned to a ciprofol or propofol group in a 2:1 ratio.The ciprofol infusion was started with a loading infusion of 0.1-0.2 mg/kg for 0.5-5.0 min,followed by an initial maintenance infusion rate of 0.30 mg·kg^(-1)·h^(-1),which could be adjusted to an infusion rate of 0.06 to 0.80 mg·kg^(-1)·h^(-1),whereas for propofol the loading infusion dose was 0.5-1.0 mg/kg for 0.5-5.0 min,followed by an initial maintenance infusion rate of 1.50 mg·kg^(-1)·h^(-1),which could be adjusted to 0.30-4.00 mg·kg^(-1)·h^(-1)to achieve-2 to+1 Richmond Agitation-Sedation Scale sedation within 6-24 h of drug administration.Results:Of the 39 enrolled patients,36 completed the trial.The median(min,max)of the average time to sedation compliance values for ciprofol and propofol were 60.0(52.6,60.0)min and 60.0(55.2,60.0)min,with median difference of 0.00(95%confidence interval:0.00,0.00).In total,29(74.4%)patients comprising 18(69.2%)in the ciprofol and 11(84.6%)in the propofol group experienced 86 treatment emergent adverse events(TEAEs),the majority being of severity grade 1 or 2.Drug-and sedation-related TEAEs were hypotension(7.7%vs.23.1%,P=0.310)and sinus bradycardia(3.8%vs.7.7%,P=1.000)in the ciprofol and propofol groups,respectively.The plasma concentration-time curves for ciprofol and propofol were similar.Conclusions:ciprofol is comparable to propofol with good tolerance and efficacy for sedation of Chinese intensive care unit patients undergoing mechanical ventilation in the present study setting.Trial registration:ClinicalTrials.gov,NCT04147416.
